|Mr. Matthew Craig Kapusta||CEO, CFO & Exec. Director||908.63k||459.12k||1972|
|Dr. Sander van Deventer M.D., Ph.D.||Co-Founder, Exec. VP of Research & Product Devel. and GM of Amsterdam||431.04k||N/A||1954|
|Dr. Alexander E. Kuta Ph.D.||Exec. VP of Operations||610.61k||2.42M||1960|
|Dr. Robert Gut M.D., Ph.D.||Chief Medical Officer & Exec. Director||747.11k||N/A||1965|
|Prof. Hugo Katus||Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany||N/A||N/A||N/A|
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS governance QualityScore as of 5 December 2019 is 5. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 2; Compensation: 5.